Connect with us

Published

on

Sam Altman, CEO of OpenAI, attends the 54th annual meeting of the World Economic Forum, in Davos, Switzerland, on Jan. 18, 2024.

Denis Balibouse | Reuters

Elon Musk is suing Microsoft-backed OpenAI and its CEO Sam Altman, among others, alleging they abandoned the company’s founding mission to develop artificial intelligence “for the benefit of humanity broadly.”

In a lawsuit filed on Thursday with a San Francisco court, Musk’s lawyers said the tech billionaire was approached in 2015 by Altman and OpenAI co-founder Greg Brockman and agreed to form a non-profit lab that would develop artificial general intelligence for the “benefit of humanity.”

A co-founder of OpenAI in 2015, Musk stepped down from the firm’s board in 2018, four years after saying that AI is “potentially more dangerous than nukes.”

“To this day, OpenAI, Inc.’s website continues to profess that its charter is to ensure that AGI benefits all of humanity.’ In reality, however, OpenAI, Inc. has been transformed into a closed-source de facto subsidiary of the largest technology company in the world: Microsoft,” the lawsuit filing said.

Musk’s lawyers said in the lawsuit that OpenAI’s focus on maximizing profits for Microsoft breaks that agreement.

“Under its new Board, it is not just developing but is actually refining an AGI to maximize profits for Microsoft, rather than for the benefit of humanity,” the filing said.

OpenAI and Microsoft were not immediately available for comment.

Musk’s lawyers said the suit was submitted “to compel OpenAI to adhere to the Founding Agreement and return to its mission to develop AGI for the benefit of humanity, not to personally benefit the individual Defendants and the largest technology company in the world.”

The legal action pits two of the world’s most prominent tech leaders against each other at a time of extraordinary hype over the future of AI.

Since debuting in Nov. 2022, OpenAI’s chatbot ChatGPT has taken the world by storm. The AI tool quickly became the fastest-growing consumer application in history and kickstarted the launch of rival chatbots from companies such as Google-parent Alphabet and Microsoft.

Both Musk and Altman have been making headlines. Musk, considered the world’s richest person, runs electrical vehicle maker Tesla, rocket and satellite maker SpaceX and bought X, formerly Twitter, for $44 billion in Oct., 2022. He recently reported the advances of the brain chip technology implants produced by his startup Neuralink.

Altman has meanwhile had a rocky relationship with OpenAI. He was suddenly fired from the company in November last year, in a move that sent shockwaves across the tech industry. The American entrepreneur — one of the leading figures in the AI boom — returned to the firm a few days later.

Continue Reading

Technology

Shares in Chinese chipmaker SMIC drop nearly 7% after earnings miss

Published

on

By

 Shares in Chinese chipmaker SMIC drop nearly 7% after earnings miss

A logo hangs on the building of the Beijing branch of Semiconductor Manufacturing International Corporation (SMIC) on December 4, 2020 in Beijing, China.

Vcg | Visual China Group | Getty Images

Shares of Semiconductor Manufacturing International Corporation, China’s largest contract chip maker, fell nearly 7% Friday after its first-quarter earnings missed estimates.

After trading on Thursday, the company reported a first-quarter revenue of $2.24 billion, up about 28% from a year earlier. Meanwhile, profit attributable to shareholders surged 162% year on year to $188 million.

However, both figures missed LSEG mean estimates of $2.34 billion in revenue and $225.1 million in net income, as well as the company’s own forecasts.

During an earnings call Friday, an SMIC representative said the earnings missed original guidance due to “production fluctuations” which sent blended average selling prices falling. This impact is expected to extend into the second quarter, they added.

For the current quarter, the chipmaker forecasted revenue to fall 4% to 6% sequentially. Gross margin is also expected to fall within the range of 18% to 20%, compared to 22.5% in the first quarter.

Still, the first quarter saw SMIC’s wafer shipments increase by 15% from the previous quarter and by about 28% year-on-year.

In the earnings call, SMIC attributed that growth to customer shipment pull in, brought by changes in geopolitics and increased demand driven by government policies such as domestic trade-in programs and consumption subsidies.

In another positive sign for the company, its first-quarter capacity utilization— the percentage of total available manufacturing capacity that is being used at any given time— reached 89.6%, up 4.1% quarter on quarter.

Demand in China for chips is extremely strong, says Benchmark's Cody Acree

“SMIC’s nearly 90% utilization rate reflects strong domestic demand for semiconductors, likely driven by smartphone and consumer electronics production,” said Ray Wang, a Washington-based semiconductor and technology analyst, adding that the demand was also reflected in the company’s strong quarterly revenue growth.

Meanwhile, the company said in the earnings call that it is “currently in an important period of capacity construction, roll out, and continuously increasing market share.”

However, SMIC’s first-quarter research and development spending decreased to $148.9 million, down from $217 million in the previous quarter.

Amid increased demand, it will be crucial for SMIC to continue ramping up their capacity, Simon Chen, principal analyst of semiconductor manufacturing at Informa Tech told CNBC.

SMIC generates most of its revenue from older-generation semiconductors, often referred to as “mature-node” or “legacy” chips, which are commonly found in consumer electronics and industrial equipment.

The state-backed chipmaker is critical to Beijing’s ambitions to build a self-sufficient semiconductor supply chain, with the government pumping billions into such efforts. Over 84% of its first-quarter revenue was derived from customers in China.

“The localization transformation of the supply chain has been strengthened, and more manufacturing demand has shifted back domestically,” a representative said Friday.

However, chip analysts say the chipmaker’s ability to increase capacity in advance chips — used in applications that demand higher levels of computing performance and efficiency at higher yields — is limited.

This is due to U.S.-led export controls, which prevent it from accessing some of the world’s most advanced chip-making equipment from the Netherlands-based ASML. 

Nevertheless, the chipmaker appears to be making some breakthroughs. Advanced chips manufactured by SMIC have reportedly appeared in various Huawei products, notably in the Mate 60 Pro smartphone and some AI processors.

In the earnings call, the company also said it would closely monitor the potential impacts of the U.S.-China trade war on its demand, noting a lack of visibility for the second half of the year.

Phelix Lee, an equity analyst for Morningstar focused on semiconductors, told CNBC that the impacts of U.S. tariffs on SMIC are limited due to most of its revenue coming from Chinese customers.

While U.S. customers make up about 8-15% of revenue on a quarterly basis, the chips usually remain and are consumed in Chinese products and end users, he said.

“There could be some disruption to chemical, gas, and equipment supply; but the firm is working on alternatives in China and other non-U.S. regions,” he added.

SMIC’s Hong Kong-listed shares have gained over 32.23% year-to-date.

Continue Reading

Technology

Amazon adds pet prescriptions to its online pharmacy

Published

on

By

Amazon adds pet prescriptions to its online pharmacy

Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021. 

Smith Collection | Gado | Getty Images

Amazon is expanding its online pharmacy to fill prescription pet medications, the company announced Thursday.

The company said it has added “hundreds of commonly prescribed pet medications” to its U.S. site, ranging from flea and tick solutions to treatments for chronic conditions.

Prescriptions are purchased via Amazon’s storefront and must be approved by a veterinarian. Online pet pharmacy Vetsource will oversee the dispensing and delivery of medications, said Amazon, adding that items are typically delivered within two to six days.

Amazon launched its digital drugstore in 2020 with the added perk of discounts and free delivery for Prime members. The company has been working to speed up prescription shipments over the past year, bringing same-day delivery to a handful of U.S. cities. Last October, Amazon set a goal to make speedy medicine delivery available in nearly half of the U.S. in 2025.

The new pet medication offerings puts Amazon into more direct competition with online pet pharmacy Chewy, as well as Walmart, which offers pet prescription delivery.

Amazon Pharmacy is part of the company’s growing stable of healthcare offerings, which also includes One Medical, the primary care provider it acquired for roughly $3.9 billion in July 2022. Amazon’s online pharmacy was born out of the company’s 2018 acquisition of online pharmacy PillPack.

WATCH: Amazon’s new Vulcan robot can ‘feel’ what it touches

Here's a first look at Vulcan, Amazon's new stowing robot that can feel what it touches

Continue Reading

Technology

Coinbase acquires crypto derivatives exchange Deribit for $2.9 billion

Published

on

By

Coinbase acquires crypto derivatives exchange Deribit for .9 billion

The Coinbase logo is displayed on a smartphone with stock market percentages on the background.

Omar Marques | SOPA Images | Lightrocket | Getty Images

Coinbase agreed to acquire Dubai-based Deribit, a major crypto derivatives exchange, for $2.9 billion, the largest deal in the crypto industry to date.

The company said Thursday that the cost comprises $700 million in cash and 11 million shares of Coinbase class A common stock. The transaction is expected to close by the end of the year.

Shares of Coinbase rose nearly 6%.

The acquisition positions Coinbase as an international leader in crypto derivatives by open interest and options volume, Greg Tusar, vice president of institutional product, said in a blog post – which could allow it take on big players like Binance. Coinbase operates the largest marketplace for buying and selling cryptocurrencies within the U.S., but has a smaller share of the global crypto market, where activity largely takes place on Binance.

Deribit facilitated more than $1 trillion in trading volume last year and has about $30 billion of current open interest on the platform.

“We’re excited to join forces with Coinbase to power a new era in global crypto derivatives,” Deribit CEO Luuk Strijers said in a statement. “As the leading crypto options platform, we’ve built a strong, profitable business, and this acquisition will accelerate the foundation we laid while providing traders with even more opportunities across spot, futures, perpetuals, and options – all under one trusted brand. Together with Coinbase, we’re set to shape the future of the global crypto derivatives market.”

Tusar also noted that Deribit has a “consistent track record” of generating positive adjusted EBITDA the company believes will grow as a combined entity.  

“One of the things we liked most about this deal is that it’s not just a game changer for our international expansion plans — it immediately diversifies our revenue and enhances profitability,” Tusar told CNBC.

The deal comes at a time when the crypto industry is riding regulatory tailwinds from the first ever pro-crypto White House. Support of the industry has fueled crypto M&A activity in recent weeks. In March, crypto exchange Kraken agreed to acquire NinjaTrader for $1.5 billion, and last month Ripple agreed to buy prime broker Hidden Road.

Don’t miss these cryptocurrency insights from CNBC Pro:

Continue Reading

Trending